ABOUT US
​Causeway Therapeutics is a clinical-stage Bio-pharmaceutical company that spun-out of the University of Glasgow in 2017 to develop novel microRNA therapies for the treatment of common musculoskeletal and age-related diseases. We have an impressive pipeline of therapies including programs targeting tendinopathy, interverbal disc disease (IVDD), osteoarthritis and skin ageing, each with potential markets over $1 Billion per annum.

​WHERE WE WORK
Causeway’s is spread over two sites in Glasgow (Scotland). Our office is located within the Clinical Innovation Zone at the Queen Elizabeth University Hospital (Europes largest hospital campus) (Photo) placing us close to the Clinicians who inform our science and importantly next to the patients suffering from the diseases we aim to treat. We are also ideally placed to access the invaluable patient samples that drive our R&D activities.  
​
​Our lab is located a short distance across the River Clyde in the 3Is at the University of Glasgow campus. Being based at the University of Glasgow campus gives us access to the state-of-the-art facilities of the Institute of Infection, Immunity and Inflammation,  where we work alongside world-leading academics clinical academics and have access to the latest cutting-edge research equipment and core research facilities, including Polyomics (RNAseq, single-cell sequencing, proteomics and bio-informatics), Flow cytometry Facility (18-colour FACS), Imaging (Super-resolution microscopy, Live imaging microscopy, in vivo imaging, multi-photon microscopy and high-throughput imaging).  Access to these technologies and the experts who run them means that Causeway’s R&D capabilities are on a par with those of large pharma.

---